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Abstract: It is known that phenylboronic acid (PBA) can target tumor tissues by binding to sialic acid,
a substrate overexpressed by cancer cells. This capability has previously been explored in the design
of targeting diagnostic probes such as Gd- and 68Ga-DOTA-EN-PBA, two contrast agents for magnetic
resonance imaging (MRI) and positron emission tomography (PET), respectively, whose potential
has already been demonstrated through in vivo experiments. In addition to its high resolution, the
intrinsic low sensitivity of MRI stimulates the search for more effective contrast agents, which, in
the case of small-molecular probes, basically narrows down to either increased tumbling time of the
entire molecule or elevated local concentration of the paramagnetic ions, both strategies resulting in
enhanced relaxivity, and consequently, a higher MRI contrast. The latter strategy can be achieved
by the design of multimeric GdIII complexes. Based on the monomeric PBA-containing probes
described recently, herein, we report the synthesis and characterization of the dimeric analogues
(GdIII-DOTA-EN)2-PBA and (GdIII-DOTA-EN)2F2PBA. The presence of two Gd ions in one molecule
clearly contributes to the improved biological performance, as demonstrated by the relaxometric
study and cell-binding investigations.
Keywords: gadolinium complexes; MRI contrast enhancement; phenylboronic acid; sialic acid;
tumor targeting
1. Introduction
Boronic acids continue to find wider applications in biomedical research, material
science, chemical synthesis and electronics [1]. In particular, the recent interest in phenyl-
boronic acid (PBA) for diagnostic and therapeutical purposes has arisen from its ability
to bind sialic acid (SA), a nine-carbon monosaccharide unit that is overexpressed as the
terminal group of glycolipids and glycoproteins on the surface of tumor cells [2], thus
making them exploitable in the design of targeting contrast agents. PBA derivatives can
reversibly form five- or six-membered cyclic boronate esters with the exocyclic polyol
chain of SA [3], and this property has already been exploited in the preparation of a few
diagnostic targeting probes [4–6]. Among them, GdIII-DOTA-EN-PBA has proven particu-
larly successful as a magnetic resonance imaging (MRI) contrast agent for in vivo tumor
targeting based on the recognition of overexpressed sialic acid [7]. This GdIII complex
bears a PBA group conjugated to a polyamino-polycarboxylic ligand for paramagnetic ions
(DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) through an aminoethy-
lamide spacer (EN = ethylenediamine) (Figure 1). It was proven that a two-site cooperative
binding mechanism takes place: on one side, the previously mentioned formation of a
cyclic boronate between the B(OH)2 moiety and the diol of the substrate; on the other side,
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recognition is enhanced by an electrostatic interaction between the negatively charged
carboxylate on the SA residue and the positively charged amine of the linker between the
macrocycle and PBA. The success of GdIII-DOTA-EN-PBA targeting led to further inves-
tigation of this ligand with the radioactive 68GaIII ion, enabling visualization of tumors
by positron emission tomography (PET) [8]. Very recently, a paper was published by our
group reporting a double improvement regarding this type of functionalized ligand: a
more efficient synthetic procedure and an enhancement in binding capability [9]. Con-
cerning the former issue, it is well-known that the amphiphilic character of boronates
causes difficulties in their preparation and purification, including solubility problems,
tendency to form oligomers or react with nucleophilic species, and the pH dependence of
the equilibrium between a boronic acid and its boronate [10]. In our synthetic approach,
we exploited solid-phase synthesis to overcome all these problems by binding the boronic
site to a suitable functionalized support (DEAM-PS resin) [11–13] for temporary protection
of the moiety, thus obtaining a final cleaner product at a higher yield [9]. This procedure
was then successfully applied to prepare an analogous ligand modified at the phenyl ring
with the introduction of two electron-withdrawing fluorine atoms in order to increase the
acidity of the phenylboronic group and, consequently, its ability to bind SA residues on the
surface of tumor cells. The switch of the boronate from the meta-position in DOTA-EN-PBA
to the para-position in the novel DOTA-EN-F2PBA allowed testing of the importance of the
formation of the cyclic boronate in the recognition mechanism, regardless of the additional
contribution of the previously mentioned amine-carboxylate electrostatic interaction. The
cell binding experiments that were carried out with the GdIII-DOTA-EN-F2PBA complex
confirmed the improved affinity that counterbalanced the loss of the electrostatic effect.
Herein, we report a further advancement in the DOTA-EN-PBA-based ligands con-
sisting of their dimeric analogues (DOTA-EN)2-PBA and (DOTA-EN)2-F2PBA (Figure 1).
Due to the intrinsic low sensitivity of MRI, the preparation of dimers or multimers (e.g.,
tetramers, hexamers, etc.) has become a common strategy to improve the performance of
MRI contrast agents by increasing the local concentration of paramagnetic ions and the
global tumbling time (τR) of the agent. A high relaxivity density (i.e., high relaxivity per
Gd ion) usually implies a significant enhancement of the relaxation rate per mass unit
of MRI agent, often referred to as mass relaxivity [14], which represents an important
parameter in molecular imaging applications. On the other hand, an increased molecular
size leads to a lengthening in τR and, in turn, a higher longitudinal relaxivity r1. Examples
of ditopic DOTA-like systems were reported by using GdIII-DOTA monoamide [15,16],
GdIII-HPDO3A [17], and GdIII-DOTA [18]. The relaxivity enhancement of these systems
as compared to monomeric Gd complexes was often very much dependent on the wa-
ter exchange rate or on the rigidity of the linker. The two novel ligands reported in the
present work, still prepared by exploiting the proven advantages of solid-phase synthesis,
are endowed with two DOTA-macrocycles connected via EN-linkers to a phenylboronic
acid or a difluorophenylboronic acid, respectively. The two resulting DOTA monoamide
(DOTAMA) macrocycles in each ligand are well known to form thermodynamically and
kinetically stable chelates with GdIII ions [19].
For consistency in the comparison, the positions of the boronic acid moiety and the
fluorine atoms with respect to the aromatic ring were maintained exactly the same as
in the monomeric ligands. The corresponding GdIII complexes of both chelates were
then prepared and fully characterized through standard 1H and 17O NMR relaxometric
techniques. Finally, the targeting abilities and contrast enhancement of the novel dimeric
(GdIII-DOTA-EN)2-F2PBA complex were investigated on suitable tumor cell cultures, i.e.,
cell cultures overexpressing a sufficient amount of SA.
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pounds. 
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2.1. Synthesis 
The first part of the synthesis of the (DOTA-EN)2-ligands (Scheme 1) started with the 
preparation of N,N’-di-Boc-2-azido-1,3-diaminopropane 1 (Boc = tert-butoxycarbonyl pro-
tecting group) according to a reported procedure [20]. The amino groups of 1,3-diamino-
2-propanol were protected with di-tert-butyl dicarbonate and then the hydroxyl group 
was activated as the corresponding mesylate and converted into an azide. 
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HBTU, HOBt, DIPEA, DMF, rt, 15 h; (iii) H2, Pd/C, rt, 3 h; (iv) THF, rt, 3 h; (v) NaBH4, THF, rt, 4 h; (vi) TFA, DCM, rt, 1 h. 
The two primary amines of 1 were deprotected by stirring the compound in 4 M HCl, 
leading to compound 2 as hydrochloride salt that was reacted directly with tris-tert-butyl-
protected DOTA in the presence of peptide coupling agents to obtain the dimer 3. The 
DOTA-precursor was, in turn, prepared converting commercial DO3A hydrobromide salt 
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The two primary amines of 1 were deprotected by stirring the compound in 4 M HCl,
leading to compound 2 as hydrochloride salt that was eacted directly with tris-tert-butyl-
protected DOTA in the presen e f p ptide coupling agents to obtain the dimer 3. The
DOTA-precursor was, in tur , prepared converting commercial DO3A hydrobromide salt
into its monoethyl ester [7] that was hydrolyzed under strong alkaline conditions into
the corresponding carboxylic acid. The azide moiety of 3 was then reduced to amine,
leading to the product 4, which was used in a reductive amination with the suitable
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formylphenylboronic acid previously immobilized on DEAM-PS resin. Final cleavage
and deprotection with TFA afforded the desired compounds. The characterization of
the intermediates and the final products was performed via IR and NMR spectroscopies
(Figures S1–S3). (DOTA-EN)2-PBA and (DOTA-EN)2-F2PBA were obtained with a final 32
and 36% yield, respectively, and the part of the process involving a boronate moiety was
easily carried out thanks to the previously mentioned advantages of solid-phase synthesis.
Such results confirm the validity of the synthetic protocol recently reported by our group
for the preparation of this type of functionalized ligand [9].
The corresponding GdIII complexes (GdIII-DOTA-EN)2-PBA and (GdIII-DOTA-EN)2-
F2PBA were prepared by mixing each ligand with a slight excess of GdCl3 hexahydrate
(Scheme 2). The unreacted GdIII was precipitated as hydroxide at pH 10 and filtered off.
The formation of the complexes was confirmed by ESI+ mass spectrometry (Figures S4
and S5). The paramagnetic complexes obtained upon lyophilization were used directly to
investigate their properties in terms of performance as MRI contrast agents and targeting
probes. The stability of the novel probes can be considered similar to the monomeric
analogue Gd-DOTA-EN-PBA such as it has been found in transmetallation studies with
endogenous ZnII ions in the presence of phosphate buffer (Figure S6) [21].
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2.2. Relaxometric Characterizations
The longitudinal relaxivity value r1 (per 1mM Gd) at 25 ◦C and 20 MHz of the binuclear
complexes is 8.7 mM−1 s−1 for (GdIII-DOTA-EN)2-PBA and 8.2 mM−1 s−1 for (GdIII-DOTA-
EN)2-F2PBA, with a ca. 40% increase compared to the values measured for the mononuclear
species (6.2 and 5.8 mM−1 s−1, respectively) [9]. The re axivity enhancement can be easily
ttribut d to a longer value of the rotational correlation time associat d wi h the larger
molecular size, c mbined with t retention of the same hydration state (q = 1) for each
metal ion. As has alrea y been notic d f r the monomeric complexes [9], the fluorinated
chelate has a slightly lower relaxivity: this can probably be ascrib d to a d crease in its
hydrophilicity induced by the fluorine atoms o the aromatic ring that affects the hydration
of the mole ule and then the rotatio al dynamics. The ob ained rel xivity values are in
agreem nt with a q = 1 ydration state, as confirmed by all DOTA monoamide-related
studies, since the first paper about GdIII-DOTAMA was reported almost 30 years ago [15].
The relaxometric characterization of each binuclear GdIII c mplex was carried out
by recording their 1H nuclear magnetic relaxation dispersion (NMRD) profiles in the
frequency range 0.01 to 70 MHz (2.34 × 10−4 − 1.64 T) at 25 and 37 ◦C (Figure 2). The
r1 values at 37 ◦C are only slightly lower than those measured at 25 ◦C, over the entire
range of investigated proton Larmor frequencies, indicating that the water exchange rate
(kex = 1/τM) might be slow. In Figure 3, the NMRD profiles at 25 ◦C of the two binuclear
compounds are compared with the two mononuclear analogues. For the GdIII dimers
a broad peak is observable at higher magnetic fields (centered at 40 MHz), typical of
Molecules 2021, 26, 1730 5 of 14
multimeric species and due to the effects induced by the increased molecular weight of the
whole molecule on the rotational correlation time (τR) of each complex (see below).
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Figure 3. Comparison between the 1H NMRD profiles of aqueous solutions of (GdIII-DOTA-EN)2-
PBA, (GdIII-DOTA-EN)2-F2PBA, GdIII-DOTA-EN-PBA nd GdIII-DOTA-EN-F2PBA. All profiles were
acquired at 25 ◦C and pH 7. The solid lines represent the best-fitting results of the experimental
data points.
It is noteworthy that the relaxivities of (GdIII-DOTA-EN)2-PBA and (GdIII-DOTA-EN)2-
F2PBA calculated per concentration of dimer are 17.4 and 16.3 mM−1 s−1, respectively.
These values imply that, in order to achieve the same MRI contrast enhancement as
obtained with the corresponding monomers, it is sufficient to use a molar amount of such
agents about 36% of that required for GdIII-DOTA-EN-PBA or GdIII-DOTA-EN-F2PBA.
First, a complete 1H and 17O NMR relaxometric study was carried out on the monomers
to obtain a more accurate analysis of the water exchange dynamics of the GdIII complexes.
Thus, the accurate value of the water exchange time τM (Table 1) was obtained by analyzing
the temperature dependence of the 17O NMR transverse relaxation rate (1/T2) and the
paramagnetic shift (∆ω) of the solvent water at 11.7 T. The experimental data, reported as
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reduced transverse relaxation rates (1/T2r) and reduced chemical shifts (∆ωr), are shown in
Figure 4. The 1H NMRD and 17O NMR data were fitted simultaneously, according to the es-
tablished theory of paramagnetic relaxation. Thus, while NMRD data were analyzed using
the standard Solomon–Bloembergen–Morgan model for the inner-sphere relaxation mech-
anism [22–24] and Freed’s model for the outer-sphere components [25], the temperature
dependence of 1/T2r and ∆ω was evaluated by using the Swift–Connick equations [26,27]
(see details in the Supplementary Materials). Due to the number of parameters implicated
in the fitting procedure, some of them were fixed to known or plausible values, namely the
hydration number (q), the GdIII-H2O distance (r), the distance of closest approach of the
outer sphere water molecules to GdIII (a) and the relative diffusion coefficient at 25 ◦C (D).
The temperature dependence of τV (correlation time for the modulation of the transient
zero-fit splitting, ZFS) and τR has been considered through their activation energies EV
(set to 1 kJ mol−1) and ER (fixed to 10 kJ mol−1). The fit was carried out using τR, ∆2
(trace of the ZFS), τV, τM, the enthalpy of activation ∆HM and the scalar Gd-17Ow coupling
constant A/h̄ as adjustable parameters. The best-fit parameters for GdIII-DOTA-EN-PBA
and GdIII-DOTA-EN-F2PBA (Table 1) show values in line with those reported for other
GdIII-DOTA monoamides [19,28], both in terms of electronic parameters (∆2and τV) and of
water exchange dynamics. In particular, τM values of 471 ns for GdIII-DOTA-EN-PBA and
486 ns for GdIII-DOTA-EN-F2PBA were determined, slightly lower than those reported for
other GdIII-DOTA monoamides [19,28,29]. Finally, the shape of the 1/T2r plot is further
confirmation of a q = 1 hydration state.
Although no variation in the water exchange parameters was expected passing from
the mononuclear to the binuclear complexes, 17O NMR data were acquired also for the
fluorinated dimer to confirm this hypothesis (Figure 4). Therefore, the simultaneous fitting
of the 17O NMR and 1H NMRD data for (GdIII-DOTA-EN)2-F2PBA and the fitting of the
NMRD profiles at 25 and 37 ◦C for (Gd III-DOTA-EN)2-PBA were carried out using the same
equations and procedure described above, resulting in the parameters shown in Table 1.
For the binuclear complexes, the higher molecular weight (MW = ca 1000 Da) implies
a slower rotational dynamic of the paramagnetic probes compared to the monomeric
analogues (MW = ca 600 Da), mirrored by the values of τR (ca 100 ps for the monomers
vs. ca 200 ps for the dimers). As mentioned above, this increase in τR is responsible
for the broad peak observed in the NMRD profiles at higher magnetic field strengths.
Unfortunately, the intermediate/long τM values (around 0.5 µs), typical of GdIII-DOTA
monoamide complexes, limit the r1 increase from mononuclear to binuclear complexes to
only 40%, lower than that observed when the water residence lifetime is lower than 100 ns
(fast exchange regime) [30].
Table 1. Selected parameters obtained from the analysis of the 1/T1 NMRD profiles at 298 K and the 17O NMR data a.





20MHzr1p [mM−1 s−1] 6.2 ± 0.1 5.8 ± 0.1 8.7 ± 0.1 8.2 ± 0.1
τR [ps] 109 ± 9 102 ± 2 212 ± 2 203 ± 2
∆2 [1019 s−2] 1.9 ± 0.1 2.1 ± 0.1 1.5 ± 0.1 1.6 ± 0.1
τv [ps] 32 ± 1 29 ± 1 40 ± 1 38 ± 1
τM [ns] 471 ± 19 486 ± 27 471b 510 ± 18
∆HM [kJ mol−1] 40 ± 4 37 ± 4 - 36 ± 1
A/h [106 rad s−1] −3.3 ± 0.1 −3.3 ± 0.1 - −3.3 ± 0.1
a The following parameters were fixed to appropriate values during the fitting procedure: q = 1; rGd-H = 3.0 Å; a = 4.0 Å;
D298 = 2.24 × 10−5 cm2 s−1; EV = 1 kJ mol−1; ER = 10 kJ mol−1. b τM value determined for the mononuclear complex.
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Figure 5. Evaluation of cell binding of Gd complexes upon their incubation with melanoma B16-F10
cells for 4 h in EBSS buffer w/o glucose at a concentration of 0.6 mM Gd. Error bars indicate ± SD
and the mean values are obtained from three independent experiments.
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A study that has recently been reported in the literature highlights that mesothelioma
cells express a high amount of SA on their surface [31–33]. Mesothelioma is the malignant
neoplasm of the mesothelial cells and is a highly aggressive tumor lacking any significant
therapies. Thus, it was decided to implement a binding test of (GdIII-DOTA-EN)2-F2PBA
with two mesothelioma cell lines (ZL34 human and AB22 murine). The results presented in
Figure 6 show a high amount of cell bound fluorinated Gd dimer that, in the case of AB22,
was similar to that found for the B16 melanoma. Since there is no evidence in the literature
for a distinctive SA expression by mesothelioma cells of various species, the difference in
binding found for AB22 and ZL34 can be explained by the intrinsic variability of SA in
these tumors.
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independent experiments.
Finally, a T1-weighted MR image of AB22 and ZL34 mesothelioma cells was acquired
(Figure 7a) and their corresponding R1 was measured (Figure 7b) showing that the amount
of internalized Gd is sufficient to generate a positive contrast, thus demonstrating that the
probe can be used to detect mesothelioma cells.
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Alfa Aesar Co. (Thermo Fisher GmbH, Kandel, Germany) and Acros Organics and were 
used without further purification. “H2O” refers to high purity water with conductivity of 
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carried out on silica plates (silica gel 60 F254, Merck 5554, Darmstadt, Germany) and vis-
ualized by UV lamp (254 nm) or stained in KMnO4, ninhydrin, bromocresol green or cur-
cumin solution as appropriate. Preparative column chromatography was carried out us-
ing silica gel (Merck Silica Gel 60, 230 ± 400 mesh) pre-soaked in the starting eluent. 
1H, 13C, 11B and 19F NMR spectra (including 1H-decoupled 13C NMR) and homo-/het-
ero-nuclear bidimensional maps were recorded on a Bruker Avance III spectrometer 
(Bruker, Milano, Italy) operating at 11.74 T, corresponding to a protonic resonance fre-
quency of 499.8 MHz. Samples were prepared in 5 mm NMR tubes by dissolving the com-
pounds in appropriate deuterated solvents. Chemical shifts are reported in ppm relative 
to TMS (0 ppm for 1H and 13C NMR), H3BO3 (0 ppm for 11B NMR) and CF3COOH (−74.4 
ppm for 19F NMR) as internal standards. For 11B NMR experiments, a quartz tube was 
used. Splitting patterns are described as singlet (s), broad singlet (bs), doublet (d), double 
doublet (dd), triplet (t), multiplet (m) or broad multiplet (bm). Coupling constants are 
reported in Hz. 
ESI mass spectra were recorded on a Waters SQD 3100. Analytical HPLC-MS was 
carried out on a Waters modular system equipped with Waters 1525 binary pump, Waters 
2487 UV/Vis and Waters SQD 3100 (ESCI ionization mode) detectors, using an XBridgeTM 
Phenyl 3.5 μm 4.6 × 150 mm column (Waters Corporation, Milford, MA, USA). 
The water proton longitudinal relaxation rates as a function of the magnetic field 
strength were measured in non-deuterated aqueous solutions on a Fast Field-Cycling Ste-
lar SmarTracer relaxometer (Stelar s.r.l., Mede (PV), Italy) over a continuum of magnetic 
field strengths from 0.00024 to 0.25 T (corresponding to 0.01–10 MHz proton Larmor fre-
quencies). The relaxometer operates under computer control with an absolute uncertainty 
in 1/T1 of ± 1%. Additional longitudinal relaxation data in the range 20–70 MHz were ob-
tained on a Stelar Relaxometer connected to a Bruker WP80 NMR electromagnet adapted 
to variable-field measurements. The exact concentration of GdIII was determined by meas-
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Figure 7. T1W image (TR = 250 ms, TE = 3.8 ms) of a phantom containing glass capillaries filled with AB22 murine
mesothelioma cells (control, 1) incubated with 0.6 mM (GdIII-DOTA-EN)2-F2PBA (2) and ZL34 human mesothelioma
cells (control, 3) incubated with 0.6 mM (GdIII-DOTA-EN)2-F2PBA (4) (a) and their corresponding values of longitudinal
relaxivities (b). Error bars indicate ±SD and the mean values are obtained from three different slices.
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3. Materials and Methods
3.1. General Remarks
All chemicals were purchased from Sigma-Aldrich Co. (Merck, St. Louis, MO, USA),
Alfa Aesar Co. (Thermo Fisher GmbH, Kandel, Germany) and Acros Organics and were
used without further purification. “H2O” refers to high purity water with conductivity
of 0.04 µS cm−1, obtained from a “Milli-Q” purification system. Bio-Rad AG 501-X8 resin
was preliminarily washed with water and methanol. Thin-layer chromatography (TLC)
was carried out on silica plates (silica gel 60 F254, Merck 5554, Darmstadt, Germany) and
visualized by UV lamp (254 nm) or stained in KMnO4, ninhydrin, bromocresol green or
curcumin solution as appropriate. Preparative column chromatography was carried out
using silica gel (Merck Silica Gel 60, 230 ± 400 mesh) pre-soaked in the starting eluent.
1H, 13C, 11B and 19F NMR spectra (including 1H-decoupled 13C NMR) and homo-
/hetero-nuclear bidimensional maps were recorded on a Bruker Avance III spectrometer
(Bruker, Milano, Italy) operating at 11.74 T, corresponding to a protonic resonance frequency
of 499.8 MHz. Samples were prepared in 5 mm NMR tubes by dissolving the compounds
in appropriate deuterated solvents. Chemical shifts are reported in ppm relative to TMS
(0 ppm for 1H and 13C NMR), H3BO3 (0 ppm for 11B NMR) and CF3COOH (−74.4 ppm
for 19F NMR) as internal standards. For 11B NMR experiments, a quartz tube was used.
Splitting patterns are described as singlet (s), broad singlet (bs), doublet (d), double doublet
(dd), triplet (t), multiplet (m) or broad multiplet (bm). Coupling constants are reported
in Hz.
ESI mass spectra were recorded on a Waters SQD 3100. Analytical HPLC-MS was
carried out on a Waters modular system equipped with Waters 1525 binary pump, Waters
2487 UV/Vis and Waters SQD 3100 (ESCI ionization mode) detectors, using an XBridgeTM
Phenyl 3.5 µm 4.6 × 150 mm column (Waters Corporation, Milford, MA, USA).
The water proton longitudinal relaxation rates as a function of the magnetic field
strength were measured in non-deuterated aqueous solutions on a Fast Field-Cycling Stelar
SmarTracer relaxometer (Stelar s.r.l., Mede (PV), Italy) over a continuum of magnetic field
strengths from 0.00024 to 0.25 T (corresponding to 0.01–10 MHz proton Larmor frequencies).
The relaxometer operates under computer control with an absolute uncertainty in 1/T1 of
± 1%. Additional longitudinal relaxation data in the range 20–70 MHz were obtained on a
Stelar Relaxometer connected to a Bruker WP80 NMR electromagnet adapted to variable-
field measurements. The exact concentration of GdIII was determined by measurement of
bulk magnetic susceptibility shifts of a tBuOH signal or by inductively coupled plasma
mass spectrometry (ICP-MS, Element-2, Thermo-Finnigan, Rodano (MI), Italy). Sample
digestion was performed with concentrated HNO3 (70%, 2 mL) under microwave heating
at 160 ◦C for 20 min (Milestone MicroSYNTH Microwave lab station equipped with an
optical fiber temperature control and HPR-1000/6M six-position high-pressure reactor,
Bergamo, Italy). The 1H T1 relaxation times were acquired by the standard inversion
recovery method with typical 90◦ pulse width of 3.5 µs and 16 experiments with 4 scans.
The temperature was controlled with a Stelar VTC-91 airflow heater equipped with a
calibrated copper constantan thermocouple (uncertainty of ±0.1 ◦C).
Variable-temperature 17O NMR measurements were recorded on a Bruker Avance
III spectrometer (11.7 T) equipped with a 5 mm probe and standard temperature control
unit. Aqueous solutions of the complexes (10–20 mM) containing 2% of the 17O isotope
(Cambridge Isotope) were used. The observed transverse relaxation rates were calculated
from the signal width at half-height.
MR images of capillaries filled with a suitable sample were acquired at 21 ◦C, 7 T on a
Bruker Avance 300 spectrometer equipped with a microimaging probe. T1W images were
acquired by using a standard MSME (Multi-Slice Multi-Echo) sequence with the following
parameters: TR = 50 ms, TE = 3.3 ms, FOV = 1 × 1 cm, slice thickness = 1 mm, matrix size
128 × 128.
Molecules 2021, 26, 1730 10 of 14
3.2. Synthesis
3.2.1. Synthesis of Precursors
1,3-Diamino-2-azidopropane dihydrochloride (2)
Boc-diamine 1 [20] (2.74 g, 8.70 mmol) was dissolved in 4 M HCl (30 mL) and dioxane
(30 mL) and stirred at room temperature overnight. The solvents were then evaporated and
the obtained amine hydrochloride salt (1.36 g, 83%) was used without further purification.
1H NMR (400 MHz, 25 ◦C, CD3OD): 4.27 (m, 1H, CH), 3.33 (dd, J2 = 13.5 Hz, J3 =
3.9 Hz, 2H, CHH’), 3.08 (dd, J2 = 13.5 Hz, J3 = 8.9 Hz, 2H, CHH’). 13C NMR (100 MHz,
25 ◦C, CD3OD): 58.9 (NH-CH2-CHN3-CH2-NH), 41.80 (NH-CH2-CHN3-CH2-NH).
DOTA(Ot-Bu)3
The DO3A monoethyl ester [7] (1.16 g, 1.93 mmol) was dissolved in 1:1 H2O/MeOH
(20 mL) and LiOH (510 mg, 21.29 mmol) was added. The solution was stirred at room
temperature overnight. Brine (30 mL) was added, and the water layer was extracted with
DCM (2 × 20 mL). The organic phase was dried over anhydrous Na2SO4, filtered and
evaporated to obtain the DOTA derivative 16 as a white solid (410 mg, 37%).
1H NMR (400 MHz, 25 ◦C, CDCl3): 2.0–3.5 (bm, ring and acetates CH2), 1.31 (s,
27H, CH3).
(DOTA(Ot-Bu)3)2-1,3-diamido-2-azidopropane (3)
Diaminoazide 2 hydrochloric salt (100 mg, 0.53 mmol) was suspended in DMF (5 mL),
DIPEA (0.92 mL, 5.28 mmol) was added, and the suspension was stirred at room tem-
perature for 30 min. Separately, a solution of DOTA(Ot-Bu)3 (607 mg, 1.06 mmol), HOBt
(143 mg, 1.06 mmol) and HBTU (402 mg, 1.06 mmol) in DMF (5 mL) was prepared and
added to the previous suspension. The mixture was stirred at room temperature overnight.
The solvent was then evaporated under reduced pressure, the residue was suspended
in DCM (50 mL) and washed with brine (3 × 25 mL). The organic layer was dried over
anhydrous NaSO4, filtered and evaporated to obtain the product as a yellowish solid
(532 mg, 82%).
1H NMR (400 MHz, 25 ◦C, CDCl3): 6.55 (m, 2H, NH), 4.11 (m, 1H, CH), 3.45–1.88 (bm,
52H, DOTA ring and acetates + CH2CH), 1.41 (s, 54H, CH3). 13C NMR (100 MHz, 25 ◦C,
CDCl3): 172.8 (COO), 165.8 (CONH), 81.8 (CCH3), 61.1 (CH), 55.4 (CH2CO), 52 + 47 (br,
CH2 ring), 51.8 (CH2CH), 27.7 (CH3). IR: 3432, 2974, 2830, 2116, 1727, 1653, 1505.
(DOTA(Ot-Bu)3)2-1,3-diamido-2-aminopropane (4)
Compound 3 (450 mg, 0.37 mmol) was dissolved in MeOH (10 mL); 10% Pd/C (45 mg)
was added and H2 was bubbled for 10 min. The suspension was then stirred overnight
under a H2 atmosphere. After filtration through Celite, the solvent was removed under
vacuum leading to the product as a white solid (378 mg, 85%).
1H NMR (400 MHz, 25 ◦C, CDCl3): 6.59 (m, 2H, NH), 4.16 (m, 1H, CH), 3.49–1.95 (bm,
52H, DOTA ring and acetates + CH2CH), 1.72 (bm, 2H, NH2), 1.45 (s, 54H, CH3). 13C NMR
(100 MHz, 25 ◦C, CDCl3): 172.8 (COO), 165.9 (CONH), 81.8 (CCH3), 55.7 (CH2CO), 54.6
(CH), 52 + 48 (br, CH2 ring), 51.9 (CH2CH), 27.9 (CH3). IR: 3500, 2976, 2829, 1722, 1653,
1538, 872.
3.2.2. General Procedure to Bind Formylphenylboronic Acids to DEAM-PS Resin
DEAM-PS resin (306 mg, 0.51 mmol) and a suitable PBA (0.68 mmol) were weighed
in a filter-syringe. Dry THF (5 mL) was added, and the reactor was shaken for 2 h. The
suspension was then filtered and washed with dry THF (3 × 5 mL).
3.2.3. Reductive Amination between 4 and PBA-DEAM-PS Resin
PBA-DEAM-PS resin (54 mg, 0.09 mmol) was weighed in a filter-syringe and sus-
pended in dry THF (5 mL). Amine 4 (103 mg, 0.09 mmol) was dissolved in dry THF (2 mL)
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and added to the reactor. The suspension was shaken for 3h and it was filtered and washed
with dry THF (2 × 5 mL). The resulting functionalized resin was resuspended in dry THF
(5 mL), NaBH4 (7 mg, 0.18 mmol) was added, and the mixture was shaken for 4h. The resin
was then filtered and washed with dry DMF (3 × 3 mL), dry DCM (5 × 3 mL) and dry
THF (3 × 3 mL).
3.2.4. Cleavage and Deprotection of (DOTA-EN)2-PBA and (DOTA-EN)2-F2PBA
DCM (2 mL) and TFA (2 mL) were added to the resin in the syringe and the suspension
was shaken overnight. After filtration and washing with TFA (3 × 3 mL), the combined
filtrates were evaporated under reduced pressure and the products were obtained as
white solids.
(DOTA-EN)2-PBA
Yield 32%, 29 mg (0.029 mmol). 1H NMR (400 MHz, 25 ◦C, D2O): 7.83 (bs, 1H, CHAr),
7.52 (bm, 2H, CHAr), 6.95 (bm, 1H, CHAr), 3.7–2.8 (bm, 53H, DOTA ring and acetates +
CH2CHCH2). 11B NMR (128 MHz, 25 ◦C, D2O): 0.019.
(DOTA-EN)2-F2PBA
Yield 36%, 33 mg (0.032 mmol). 1H NMR (400 MHz, 25 ◦C, CDCl3): 7.46 (bm, 1H,
CHAr), 7.31 (bm, 1H, CHAr), 3.8–3.0 (bm, 53H, DOTA ring and acetates + CH2CHCH2).
11B NMR (128 MHz, 25 ◦C, D2O): 0.019. 19F NMR (376 MHz, 25 ◦C, D2O): −132.86 (d,
J3 = 21.2 Hz, CFCB), −146.97 (d, J3 = 21.2 Hz, CFCCH2).
3.2.5. General Procedure for the Preparation of GdIII complexes
The PBA-ligand (0.032 mmol) was dissolved in H2O (10 mL). GdCl3·6H2O (17 mg,
0.045 mmol) was added and the mixture was stirred overnight at pH 7 and room tem-
perature. The pH was increased to ×≈ 10 by dropwise addition of 0.1 M NaOH, and
the resulting precipitate was filtered off. The pH of the filtrate was then returned to 7 by
dropwise addition of 0.1 M HCl.
3.2.6. Cell Lines and Incubation Protocol
Mouse melanoma (B16-F10) cell lines were purchased from the American Type Culture
Corporation. Melanogenic B16-F10 cells were obtained by growing cells in standard DMEM
(Lonza) medium supplemented with 3.7 mg/mL sodium bicarbonate, 4 mM glutamine and
10% FBS (v/v). Mouse mesothelioma (AB22) cell lines were obtained from Sigma-Aldrich
and they were cultured in RPMI medium (Lonza, Basel, Switzerland) supplemented with
25 mM Hepes, 10% (v/v) FBS and 2mM glutamine. Human mesothelioma (ZL34) cell line
was obtained from Sigma Aldrich. The cells were cultured in DMEM–Ham’s F12 (Lonza)
containing 2.5 mM glutamine and supplemented with 15% (v/v) FBS. All media contained
100 U/mL penicillin and 100 U/mL streptomycin. All the cell lines were maintained in a
humidified incubator at 37 ◦C, 5% CO2.
For the cell binding experiments, 1.4 × 106 B16-F10, 4.5 × 105 ZL34 and 3 × 105 AB22
were seeded in T25 flasks. After 48 h for B16-F10 and ZL34 and after 24 h for AB22, the
cells were incubated with 0.6 mM Gd (GdIII-DOTA-EN)2-F2PBA in EBSS (Earle’s Balanced
Salts Solution) w/o glucose for 4 h at 37 ◦C, 5% CO2. All the incubations were performed
at 37 ◦C, 5% CO2. At the end of the incubation, cells were washed three times with 3 mL
ice-cold PBS and detached with 1mM EDTA. ZL34 and AB22 cells were also transferred
into glass capillaries for MRI analysis. Cells were collocated in glass capillaries inside an
agar phantom and MR images were acquired using a standard T1-weighted multi slice
spin echo sequence (TR (repetition time)/TE (echo time)/NEX number of excitations) =
250/3.7/6, FOV (field of view) = 1.2 cm) on a Bruker Avance300 spectrometer (7T) provided
with a Micro 2.5 microimaging probe (Bruker BioSpin, Ettlingen, Germany). T1 relaxation
times were determined using a standard Saturation Recovery Spin Echo. Finally, all cell
samples were transferred in falcon tubes and sonicated at 30% of power for 30 s in ice. The
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Gd content of each cell sample lysate was determined by the ICP-MS technique (see below).
The milligrams of proteins, proportional to the number of cells, of each cell sample lysate,
were evaluated by the Bradford assay (BioRad, Hercules, CA, USA) using bovine serum
albumin as a standard.
3.2.7. Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
Gd content from cell samples was determined using inductively coupled plasma
mass spectrometry (ICP-MS) (Element-2; Thermo-Finnigan, Rodano (MI), Italy). Sample
digestion was performed using a high-performance Microwave Digestion System (ETHOS
UP Milestone, Bergamo, Italy) after the addition of concentrated HNO3 (70%) to cell
lysates (1:1), in a final volume of 0.4 mL. The calibration curve was obtained using four Gd
absorption standard solutions (Sigma-Aldrich) in the range 0.1–0.004 µg/mL.
4. Conclusions
In this work, the synthesis and characterization of two novel dimeric ligands and
their GdIII complexes is reported. Both (DOTA-EN)2-PBA and (DOTA-EN)2-F2PBA (im-
provement of previously reported monomeric analogous species) bear a phenylboronic
acid that is meant to be exploited to target sialic acid, overexpressed by cancer cells. The
solid-phase approach allowed obtaining of ligands at good yields and with very sim-
ple work-up processes. The corresponding Gd complexes were prepared according to a
standard procedure and their relaxometric properties were evaluated by recording the
respective NMRD profiles and by studying the temperature dependence of the 17O NMR
transverse relaxation rate and the paramagnetic shift of the solvent water. As expected, the
higher Gd content and the bigger size (translating into a longer rotational correlation time
τR) led to an average 40% improvement in the relaxivity values for (GdIII-DOTA-EN)2-PBA
and (GdIII-DOTA-EN)2-F2PBA (8.71 and 8.16 mM−1 s−1, respectively at 20 MHz and 25 ◦C)
compared to those previously reported for the corresponding monomeric analogues (6.24
and 5.80 mM−1 s−1, respectively). This translates, in principle, into a much lower amount
(about 36%) of dimeric Gd-chelates that is necessary to administer in order to obtain the
same MRI contrast enhancement compared to the corresponding Gd monomers. By fitting
the experimental data for both monomeric and dimeric species, the main relaxometric
parameters were determined, including the water exchange time τM (ca. 470 ns) and the
rotational correlation time τR that, as anticipated, is about double for the Gd dimers (ca.
200 ps) with respect to the monomers (ca. 100 ps) due to the higher molecular weight.
Finally, the binding abilities of (GdIII-DOTA-EN)2-F2PBA were investigated by com-
paring its internalization by melanoma and mesothelioma tumor cells: in both cases, a good
amount of Gd was detected inside the cells upon incubation, which was also sufficient
to produce a significant contrast effect in phantom MR images. Therefore, the reported
complexes, and particularly (GdIII-DOTA-EN)2-F2PBA, improved in terms of both the
number of chelates (two GdIII-DOTA units) and the acidity of the boronic moiety (because
of the presence of two electron-withdrawing halogen atoms), were confirmed to repre-
sent a promising way to develop efficient targeting contrast agents for various diagnostic
techniques such as MRI, PET and SPECT. Moreover, the presence of one boron atom on
(GdIII-DOTA-EN)2-F2PBA opens perspective for its use as a boron carrier for Boron Neu-
tron Capture Therapy (BNCT). This alternative radiotherapy, thanks to its ability to hit the
tumor with a selectivity at the cellular level, is particularly effective in the treatment of
diffuse tumors such as mesothelioma [34–36].
Supplementary Materials: The following are available online, Equations used for fitting of 1H NMR
profiles and 17O NMR relaxivity data Figures S1–S3: NMR spectra, Figures S4 and S5: ESI-MS spectra,
Figure S6: transmetallation data. References [21–26,37–39] are cited in the Supplementary Materials.
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